A peptide certificate of analysis is easiest to understand when it is treated as a compact analytical report—not as a universal seal of quality. A useful COA connects a named material to a specific batch, lists the methods used, reports measured results, and states the applicable specification. The document is only as informative as the sampling plan, methods, raw data, and traceability behind it.
Regulatory analytical guidance separates several questions that are often collapsed into one marketing claim: identity, assay or content, purity, impurities, and other quality attributes. Those questions may require different procedures. A single percentage, even one reported to several decimal places, cannot answer all of them.[1][2]
Start with batch traceability
Before interpreting an instrument result, confirm that the COA can be connected to the material being reviewed. The batch or lot identifier on the document should match the identifier on the container. The compound name, sequence or formula where appropriate, test date, laboratory identity, and report identifier should be visible. A generic report with no batch relationship provides much weaker evidence than a batch-specific document.
- Batch or lot number that matches the container
- Material name and, when relevant, sequence, formula, salt form, or modification
- Date of analysis and report identifier
- Test method, result, units, and acceptance criterion
- Testing laboratory identity and an authorized review or approval
HPLC purity is a chromatographic measurement
Reversed-phase high-performance liquid chromatography (RP-HPLC) separates sample components according to how they interact with the stationary phase and mobile phase. For peptides, the chromatogram can reveal a main peak and smaller peaks from related substances or degradation products. The reported area percentage is typically the main peak area divided by the total integrated area under the defined method.[3]
That number is method-dependent. Column chemistry, gradient, detection wavelength, integration settings, sample preparation, and which peaks are included can change what is observed. A chromatographic area percentage is not automatically the same as the fraction of total vial mass that is peptide. Water, counterions, salts, and some non-UV-absorbing components may not be represented in the same way.
Mass spectrometry addresses molecular identity
Mass spectrometry measures mass-to-charge ratios of ionized molecules. When the observed mass is consistent with the calculated mass, the result supports molecular identity. LC-MS can combine chromatographic separation with mass detection, while tandem MS can add structural information by examining fragmentation patterns.[4]
Even mass agreement has limits. Isomers, stereochemical variants, or certain sequence changes can require additional or orthogonal methods. Research on chiral peptide impurities illustrates why an intact mass alone does not resolve every possible structural question.[5] The correct conclusion is therefore specific: a result may support expected molecular mass without proving every structural attribute.
Purity, identity, and content are not synonyms
- Identity asks: Is the detected material consistent with the compound named on the report?
- Chromatographic purity asks: Under this method, what fraction of integrated signal belongs to the main peak?
- Assay or content asks: How much target material is present per unit mass, volume, or container?
- Impurity testing asks: Which unwanted species are present, and at what levels?
- Other attributes may include water, residual solvents, counterions, elemental impurities, bioburden, or endotoxin—only when relevant and actually tested.
What a COA does not establish
An HPLC chromatogram and a mass spectrum do not by themselves establish sterility, absence of endotoxin, biological activity, stability through a claimed shelf life, or suitability for a particular experiment. Those conclusions require appropriate methods, specifications, controls, and often stability data. Likewise, a laboratory accreditation statement should be read for its actual scope; it does not mean that every method or sample is covered by every accreditation.
Practical reading rule Translate every claim into a measurement: What property was tested, by which method, on which batch, against what criterion, and with what result? If one of those links is missing, the conclusion should be narrowed.
A reproducibility-minded review
For experimental planning, the best COA is not necessarily the one with the largest purity number. It is the one that makes its scope clear, links results to a batch, uses methods fit for the stated purpose, and avoids implying conclusions the data do not support. That level of documentation helps researchers decide whether additional incoming testing is appropriate for their specific protocol.
Frequently asked questions
Does 99% HPLC purity mean 99% of the vial mass is peptide?
Not necessarily. HPLC area percentage describes the relative integrated signal under a defined chromatographic method. Total mass can also include water, counterions, salts, and other components. A separate assay or content method is needed to answer a mass-content question.
Can mass spectrometry replace HPLC?
Usually they answer different questions. HPLC is commonly used to separate components and estimate chromatographic purity; mass spectrometry supports molecular-mass identity. Orthogonal methods provide a more complete picture.
Does a COA prove that a material is suitable for every study?
No. Suitability depends on the protocol, matrix, sensitivity to impurities, and quality attributes required for that study. Researchers may need additional incoming or method-specific testing.
References
- FDA: Analytical Procedures and Methods Validation for Drugs and Biologics — Guidance addressing identity, strength, quality, purity, and potency methods.
- ICH Q2(R2): Validation of Analytical Procedures — Guidance covering procedures used for identity, assay, purity, and impurity measurements.
- Mant et al.: HPLC Analysis and Purification of Peptides — Review of major HPLC modes used for peptide analysis and purification.
- Characterization of Synthetic Peptide Therapeutics Using Mass Spectrometry — Review of mass-spectrometric characterization of synthetic peptides and impurities.
- Strege et al.: Enantiomeric Purity Analysis of Synthetic Peptide Therapeutics — Study describing chiral HPLC--ESI-MS/MS analysis of D-isomer impurities.
Related methods articles
- How Synthetic Peptides Are Made: A Plain-Language Guide to SPPS
- What Does Lyophilized Mean? The Science of Freeze-Dried Peptides
- Why Peptide Stability Is Sequence-Dependent
This article summarizes publicly available research for educational purposes and does not constitute medical advice, a therapeutic claim, or a recommendation for human use. Products referenced are sold for laboratory research use only.